Nano Antibodies Market Introduction
Nano antibodies are a novel class of proprietary therapeutic proteins based on single-domain antibody fragments that contain unique structural and functional properties of naturally-occurring heavy chain only antibodies. Nano antibodies, also known as nAb, are single-domain VHH antibodies derived from Camelidae. Compared to conventional monoclonal and polyclonal antibodies, nAbs has few advantages such as small size, high affinity, and unsurpassed stability. Nano antibodies enable rapid generation and large-scale production of novel biological therapeutics that have potential in a range of human diseases. The technology is used to develop heavy-chain antibodies that contain single variable domain (VHH) and two constant domains (CH2, CH3). Due to small size and unique structure, nano antibodies act as ideal building blocks for generation of biological drugs.
Global Nano Antibodies Market - Competitive Landscape
The VHH antibody has higher probability to adopt identical intra and extracellular folding. Hence, nano antibodies are used for intracellular probing. Moreover, high stability and suprmolecular assembly of antibody makes it an ideal alternative to monoclonal or polyclonal antibodies. Hence, companies are investing on more research and development for product development and approval process in different regions.
To Know the Segments Analyzed in the Nano Antibodies Market Report, Ask for a Brochure here
Ablynx, a Sanofi company, is engaged in the development of nano antibodies, a proprietary therapeutic protein based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Nano antibodies are used in the treatment of a range of serious and life-threatening human diseases. Ablynx advances a portfolio of nano antibodies based therapeutic programs in several major disease areas such as inflammation, hematology, immuno-oncology, and oncology.
Alphamab Co. Ltd.
Alphamab Co. Ltd. was established in early 2009 by Dr. Ting Xu. The company has strategic alliances with the Shanghai Institute of Materia Medica, the Chinese Academy of Science, the Southeast University, and Thermo Scientific as part of its open drug discovery platform. Currently, Alphamab has more than 30 active projects, including biosimilars, novel mAbs & engineered version of mAbs, and proteins.
Global Nano Antibodies Market Dynamics
High Prevalence of Chronic Diseases Drives Demand for Nano Antibodies
The global nano antibodies market is driven primarily by high prevalence of chronic diseases such as cancer, rare blood disorders, and diabetes. Increase in incidence of inflammation among the geriatric population due to infection and surgery and rise in hematology related disorders, especially among the young population due to increase in blood transfusion during surgery or trauma, are the other factors projected to propel the global nano antibodies market.
Owing to the increasing problem of cancer disease & diagnostic procedures, nano antibodies are finding wide application to be used among the practitioners and non-specialists for practice and surgery. Moreover, in the past few years, nano antibodies have been extensively used in oncology and hematology procedures for the treatment of life-threatening diseases.
Manufacturers Focus on Innovative Techniques to Enter Developing Nano Antibodies Market
Manufacturers in the global nano antibodies market are increasingly investing in research & development to find new and innovative techniques to develop modified nano antibodies. These also focus on offering highly-efficient and reliable nano antibodies to provide better protection against binding of antibody to antigen associated with cancer or other infectious diseases.
To Know More about TMRs Unique Offerings for Nano Antibodies Market, Request a Custom Report here
The global nano antibodies market is highly fragmented, with the presence of small number of manufacturers, especially in the developing countries. Emergence of new technologies for delivering the antibodies and high protective structure compared to monoclonal & polyclonal antibodies are factors anticipated to augment the global market. Moreover, with increasing number of joint partnership research, product differentiation has become vital to gain competitive edge in the global nano antibodies market.
Inherent Immunogenicity of Nano Antibodies likely to Restrain Market
One of the key factors hampering the growth of the global nano antibodies market is the inherent immunogenicity of the foreign protein toxin. However, in response to the growing demand for nano antibodies by consumers, companies are focusing on developing new nano antibodies with low capacitance to provide protection against diseases. Moreover, single use of nano antibodies reproduces tumor growth in few cases which is expected to restrain the global market during forecast period.
Global Nano Antibodies Market Segmentation
In terms of type, the global nano antibodies market can be classified into:
- Monovalent Nano Antibody
- Multivalent Nano Antibody
- Fusion Nano Antibody
Based on application, the global nano antibodies market can be categorized into:
- Live Cell Imaging
- Fluorescent Protein Enhancement
In terms of end-user, the global nano antibodies market can be divided into:
- Research Laboratories & Clinics
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.